Ibrutinib Shows High Response Rate in Mantle-Cell Lymphoma

Phase II trial results of the targeted agent ibrutinib in relapsed or refractory mantle-cell lymphoma show that the drug led to promising and durable responses.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news